Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 20/20 | 0.80 |
| ▸ | DRD4 | P21917 | 10/20 | 0.77 |
| ▸ | DRD3 | P35462 | 10/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3154859 | 0.99 | DRD2 (0.79) | DRD2DRD4DRD3 | |
| SCHEMBL3157625 | 0.93 | DRD2 (0.81) | DRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL3153054 | 0.92 | DRD2 (0.80) | DRD2DRD4DRD3 | |
| SCHEMBL3154861 | 0.92 | DRD2 (0.73) | DRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL3157452 | 0.91 | DRD2 (0.72) | DRD2DRD4DRD3 | |
| SCHEMBL3162893 | 0.90 | DRD2 (0.77) | DRD2DRD4DRD3 | |
| SCHEMBL3261679 | 0.90 | DRD2 (0.72) | DRD2DRD4DRD3 | |
| SCHEMBL8078 | 0.89 | DRD2 (1.00) | DRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL3148424 | 0.89 | DRD2 (0.76) | DRD2DRD4DRD3 | |
| SCHEMBL3157102 | 0.88 | DRD2 (0.61) | DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247420-B2 | Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents | REVIVA PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| EP-2162135-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINONE BASED ATYPICAL ANTIPSYCHOTIC AGENTS | Reviva Pharmaceuticals, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008144764-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINONE BASED ATYPICAL ANTIPSYCHOTIC AGENTS | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | GRIN2D, GRIN2C, AP3D1 | DRD2 26/4885DRD4 38/4885DRD3 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.